Huvepharma announced Sept. 5 that it acquired the Animal Health division of Neovia from InVivo Group, a move that will expand its focus on livestock animal health products in the European Union.

The acquisition includes Qalian France, Meriel France (hygiene line), Qalian Portugal and Qalian Italy.

“We’re very excited about this addition to our EU animal health business,” said Christian Vervaet, EU sales director for Huvepharma. “This acquisition furthers Huvepharma’s strategy in creating a balanced portfolio of animal health products and enhancing our presence in Europe and our international markets. We will be in a better position to serve our customers with an extended high-quality product range, the Qalian team and the complementary production facilities.”

Qalian France general manager Alex Klein added, “We’re pleased to join Huvepharma’s internationally recognized animal health company. This move will provide us with resources to quickly bring new solutions to veterinarians and producers. It will also allow us to accelerate the international development of our ranges of products.”

The acquisition includes Qalian and Meriel production facilities in Segré and St. Etienne in France and Carpi in Italy and the branded veterinary pharmaceuticals (drugs and premix), animal dietetics and hygiene product lines.

“Huvepharma and Qalian are strong, complementary businesses focused on providing real solutions for animal health,” Vervaet said.

Qalian and Meriel represent the Animal Health division of Neovia -- the nutrition and animal health subsidiary of InVivo Group. Qalian’s activities are focused on livestock animals. Qalian is a leading player in France and abroad, providing customers with veterinary drugs, medicated premix, animal dietetics and hygiene solutions.

Huvepharma is a fast-growing global pharmaceutical company with a focus on developing, manufacturing and marketing human and animal health products. The company also manufactures and markets enzymes for food, feed and industrial applications. Huvepharma is a privately owned company headquartered in Sofia, Bulgaria.

Huvepharma has representative offices and subsidiaries in Bulgaria, Belgium, Poland, China, Taiwan, Thailand, the U.S., Russia, India, Brazil and Turkey.